Buy Orforglipron (Foundayo) online

Price: from 13,052 to 18,908 UAH

Known as original brand(s)

Foundayo

Buy Orforglipron (Foundayo) online with delivery. Browse medicines that contain Orforglipron, compare doses and prices.

Orforglipron is an innovative, non-peptide, orally administered selective glucagon-like peptide-1 (GLP-1) receptor agonist. Unlike traditional peptide-based GLP-1 receptor agonists (such as semaglutide or dulaglutide), orforglipron is a small molecule compound that provides high oral bioavailability without requiring special absorption enhancers or strict food and water restrictions.

The mechanism of action of orforglipron involves selective activation of the GLP-1 receptor. It stimulates glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and acts on central satiety centers in the brain. This results in reduced hunger, lower caloric intake, and effective glycemic control.

Clinical use of orforglipron demonstrates significant and sustained weight reduction in patients with obesity or overweight, as well as robust glycemic control in type 2 diabetes through a convenient once-daily oral dosing regimen.

Wikipedia page
Orforglipron (Foundayo)

Indications

Orforglipron is indicated in endocrinology and metabolism for the following applications:

  • Chronic Weight Management: Long-term weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) in the presence of at least one weight-related comorbidity (e.g., hypertension, dyslipidemia, type 2 diabetes).
  • Type 2 Diabetes Mellitus: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Dosage and administration

Orforglipron is formulated for once-daily oral administration:

  • Recommended Schedule: Administered orally once daily, at any time of day, with or without food and water.
  • Dose Titration: Start at 0.8 mg daily for the first 4 weeks, then increase the dose stepwise no more often than every 4 weeks: 2.5 mg → 5.5 mg → 9 mg → 14.5 mg → 17.2 mg. The maintenance dose is 9 mg, 14.5 mg or 17.2 mg daily as decided by the physician; the maximum dose is 17.2 mg once daily.
  • Administration Method: Swallow tablets whole with water. No fasting restrictions are required prior to or after dosing.
  • Missed Dose: If a dose is missed, skip the missed dose and resume with the next planned daily dose. Do not double doses.

Orforglipron is contraindicated in the following cases:

  • Thyroid Carcinoma History: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • Hypersensitivity: Known hypersensitivity to orforglipron or any formulation excipients.
  • Pregnancy and Lactation: Pregnancy and breastfeeding periods.
  • Type 1 Diabetes: Not indicated for treatment of type 1 diabetes mellitus or diabetic ketoacidosis.
  • Severe Gastrointestinal Disease: Severe gastroparesis or active inflammatory bowel disease.

Treatment with orforglipron may cause the following adverse reactions (primarily gastrointestinal):

  • Gastrointestinal System: Nausea, vomiting, diarrhea, constipation, dyspepsia, eructation, and abdominal pain (typically transient and dose-dependent).
  • Metabolism and Nutrition: Decreased appetite, hypoglycemia (mainly when co-administered with insulin secretagogues or insulin).
  • Hepatobiliary & Pancreatic: Cholelithiasis, gallbladder disease, and rare cases of acute pancreatitis.
  • General Disorders: Fatigue, dizziness, and headache.

Frequently Asked Questions

Orforglipron is an investigational, orally bioavailable, non-peptide small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist. Unlike injectable peptide-based therapies (such as semaglutide or tirzepatide) or oral peptide formulations, orforglipron is a non-peptidic compound. It acts as an allosteric agonist by binding within the transmembrane core of the GLP-1 receptor. Its small-molecule architecture resists enzymatic degradation and ensures consistent oral absorption, enabling once-daily administration without the strict food, water, or fasting constraints associated with peptide tablets.
Orforglipron is indicated for chronic weight management in adults with obesity or overweight accompanied by weight-related comorbidities, as well as for glycemic control in adults with type 2 diabetes. By enhancing glucose-dependent insulin secretion, suppressing glucagon release, delaying gastric emptying, and engaging central satiety pathways, orforglipron reduces appetite and caloric intake. This results in significant body weight loss and clinically meaningful reductions in glycated hemoglobin (HbA1c) levels.
Orforglipron is taken orally once daily at the same time each day, with or without food and with no special water-volume requirements. To reduce gastrointestinal side effects, treatment starts at 0.8 mg daily for the first 4 weeks, and the dose is then increased in steps no more often than every 4 weeks: 2.5 mg → 5.5 mg → 9 mg → 14.5 mg → 17.2 mg. The maintenance dose (9 mg, 14.5 mg or 17.2 mg daily) is chosen by the physician; the maximum dose is 17.2 mg once daily.
Consistent with the GLP-1 receptor agonist class, the most common adverse events associated with orforglipron are gastrointestinal, including nausea, vomiting, diarrhea, constipation, reduced appetite, and dyspepsia. These reactions are predominantly mild-to-moderate in intensity, occur most frequently during the initial dose-escalation phase, and tend to diminish over time. Patients can manage these symptoms by eating smaller meals, avoiding rich or greasy foods, staying well-hydrated, and strictly adhering to the recommended dose-titration schedule.
Orforglipron is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC), in those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in individuals with known hypersensitivity to the drug. Caution is required in patients with a history of pancreatitis, severe active gastrointestinal disease (such as gastroparesis), or significant renal impairment. Routine monitoring of pancreatic enzyme levels, renal function parameters, and blood glucose metrics is advised throughout the treatment course.

Medicines containing Orforglipron

-7%
Foundayo 14.5
View
Eli Lilly

Foundayo 14.5

Orforglipron
14.5 mg 30 tablets
17612₴ 18998₴
-7%
Foundayo 17.2
View
Eli Lilly

Foundayo 17.2

Orforglipron
17.2 mg 30 tablets
18908₴ 20428₴
-7%
Foundayo 0.8
View
Eli Lilly

Foundayo 0.8

Orforglipron
0.8 mg 30 tablets
13052₴ 14081₴
-7%
Foundayo 2.5
View
Eli Lilly

Foundayo 2.5

Orforglipron
2.5 mg 30 tablets
13678₴ 14751₴
-7%
Foundayo 5.5
View
Eli Lilly

Foundayo 5.5

Orforglipron
5.5 mg 30 tablets
14975₴ 16181₴
-7%
Foundayo 9
View
Eli Lilly

Foundayo 9

Orforglipron
9 mg 30 tablets
16628₴ 17969₴
✅ All products loaded (6)

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00